{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T22:32:48Z","timestamp":1791325968213,"version":"4.3.1"},"reference-count":20,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"16","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCO"],"published-print":{"date-parts":[[2012,6,1]]},"abstract":"<jats:sec><jats:title>Purpose<\/jats:title><jats:p>This phase I study evaluated elotuzumab, lenalidomide, and dexamethasone in patients with relapsed or refractory multiple myeloma (MM).<\/jats:p><\/jats:sec><jats:sec><jats:title>Patients and Methods<\/jats:title><jats:p>Three cohorts were enrolled and treated with elotuzumab (5.0, 10, or 20 mg\/kg intravenously) on days 1, 8, 15, and 22 of a 28-day cycle in the first two cycles, and days 1 and 15 of each subsequent cycle; lenalidomide 25 mg orally [PO] on days 1 to 21; and dexamethasone 40 mg PO weekly. Dose-limiting toxicities (DLTs) were assessed during cycle 1 of each cohort, and clinical responses were evaluated during each cycle. The first five patients received up to six cycles of therapy; subsequent patients were treated until disease progression.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Twenty-nine patients with advanced MM and a median of three prior MM therapies were enrolled; 28 patients were treated, three each in the 5.0-mg\/kg and 10-mg\/kg cohorts and 22 in the 20-mg\/kg cohort. No DLTs were observed up to the maximum proposed dose of 20 mg\/kg. The most frequent grade 3 to 4 toxicities were neutropenia (36%) and thrombocytopenia (21%). Two patients experienced a serious infusion reaction (one grade 4 anaphylactic reaction and one grade 3 stridor) during the first treatment cycle. Objective responses were obtained in 82% (23 of 28) of treated patients. After a median of 16.4 months follow-up, the median time to progression was not reached for patients in the 20-mg\/kg cohort who were treated until disease progression.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>The combination of elotuzumab, lenalidomide, and low-dose dexamethasone was generally well tolerated and showed encouraging response rates in patients with relapsed or refractory MM.<\/jats:p><\/jats:sec>","DOI":"10.1200\/jco.2011.37.2649","type":"journal-article","created":{"date-parts":[[2012,5,1]],"date-time":"2012-05-01T05:31:22Z","timestamp":1335850282000},"page":"1953-1959","source":"Crossref","is-referenced-by-count":249,"title":["Elotuzumab in Combination With Lenalidomide and Low-Dose Dexamethasone in Relapsed or Refractory Multiple Myeloma"],"prefix":"10.1200","volume":"30","author":[{"given":"Sagar","family":"Lonial","sequence":"first","affiliation":[{"name":"Sagar Lonial and Jonathan L. Kaufman, Winship Cancer Institute, Emory University, Atlanta, GA; Sagar Lonial, Ravi Vij, Jonathan L. Kaufman, and Sundar Jagannath, Multiple Myeloma Research Consortium, Norwalk, CT; Ravi Vij, Washington University School of Medicine, St. Louis, MO; Jean-Luc Harousseau, Institut de Canc\u00e9rlogie de l'Ouest Ren\u00e9 Gauducheau, Saint Herblain; Philippe Moreau, University Hospital, Nantes; Thierry Facon, Xavier Leleu, Service des Maladies du Sang Hopital Claude Huriez, Lille,..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ravi","family":"Vij","sequence":"additional","affiliation":[{"name":"Sagar Lonial and Jonathan L. Kaufman, Winship Cancer Institute, Emory University, Atlanta, GA; Sagar Lonial, Ravi Vij, Jonathan L. Kaufman, and Sundar Jagannath, Multiple Myeloma Research Consortium, Norwalk, CT; Ravi Vij, Washington University School of Medicine, St. Louis, MO; Jean-Luc Harousseau, Institut de Canc\u00e9rlogie de l'Ouest Ren\u00e9 Gauducheau, Saint Herblain; Philippe Moreau, University Hospital, Nantes; Thierry Facon, Xavier Leleu, Service des Maladies du Sang Hopital Claude Huriez, Lille,..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Luc","family":"Harousseau","sequence":"additional","affiliation":[{"name":"Sagar Lonial and Jonathan L. Kaufman, Winship Cancer Institute, Emory University, Atlanta, GA; Sagar Lonial, Ravi Vij, Jonathan L. Kaufman, and Sundar Jagannath, Multiple Myeloma Research Consortium, Norwalk, CT; Ravi Vij, Washington University School of Medicine, St. Louis, MO; Jean-Luc Harousseau, Institut de Canc\u00e9rlogie de l'Ouest Ren\u00e9 Gauducheau, Saint Herblain; Philippe Moreau, University Hospital, Nantes; Thierry Facon, Xavier Leleu, Service des Maladies du Sang Hopital Claude Huriez, Lille,..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thierry","family":"Facon","sequence":"additional","affiliation":[{"name":"Sagar Lonial and Jonathan L. Kaufman, Winship Cancer Institute, Emory University, Atlanta, GA; Sagar Lonial, Ravi Vij, Jonathan L. Kaufman, and Sundar Jagannath, Multiple Myeloma Research Consortium, Norwalk, CT; Ravi Vij, Washington University School of Medicine, St. Louis, MO; Jean-Luc Harousseau, Institut de Canc\u00e9rlogie de l'Ouest Ren\u00e9 Gauducheau, Saint Herblain; Philippe Moreau, University Hospital, Nantes; Thierry Facon, Xavier Leleu, Service des Maladies du Sang Hopital Claude Huriez, Lille,..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Moreau","sequence":"additional","affiliation":[{"name":"Sagar Lonial and Jonathan L. Kaufman, Winship Cancer Institute, Emory University, Atlanta, GA; Sagar Lonial, Ravi Vij, Jonathan L. Kaufman, and Sundar Jagannath, Multiple Myeloma Research Consortium, Norwalk, CT; Ravi Vij, Washington University School of Medicine, St. Louis, MO; Jean-Luc Harousseau, Institut de Canc\u00e9rlogie de l'Ouest Ren\u00e9 Gauducheau, Saint Herblain; Philippe Moreau, University Hospital, Nantes; Thierry Facon, Xavier Leleu, Service des Maladies du Sang Hopital Claude Huriez, Lille,..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amitabha","family":"Mazumder","sequence":"additional","affiliation":[{"name":"Sagar Lonial and Jonathan L. Kaufman, Winship Cancer Institute, Emory University, Atlanta, GA; Sagar Lonial, Ravi Vij, Jonathan L. Kaufman, and Sundar Jagannath, Multiple Myeloma Research Consortium, Norwalk, CT; Ravi Vij, Washington University School of Medicine, St. Louis, MO; Jean-Luc Harousseau, Institut de Canc\u00e9rlogie de l'Ouest Ren\u00e9 Gauducheau, Saint Herblain; Philippe Moreau, University Hospital, Nantes; Thierry Facon, Xavier Leleu, Service des Maladies du Sang Hopital Claude Huriez, Lille,..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan L.","family":"Kaufman","sequence":"additional","affiliation":[{"name":"Sagar Lonial and Jonathan L. Kaufman, Winship Cancer Institute, Emory University, Atlanta, GA; Sagar Lonial, Ravi Vij, Jonathan L. Kaufman, and Sundar Jagannath, Multiple Myeloma Research Consortium, Norwalk, CT; Ravi Vij, Washington University School of Medicine, St. Louis, MO; Jean-Luc Harousseau, Institut de Canc\u00e9rlogie de l'Ouest Ren\u00e9 Gauducheau, Saint Herblain; Philippe Moreau, University Hospital, Nantes; Thierry Facon, Xavier Leleu, Service des Maladies du Sang Hopital Claude Huriez, Lille,..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier","family":"Leleu","sequence":"additional","affiliation":[{"name":"Sagar Lonial and Jonathan L. Kaufman, Winship Cancer Institute, Emory University, Atlanta, GA; Sagar Lonial, Ravi Vij, Jonathan L. Kaufman, and Sundar Jagannath, Multiple Myeloma Research Consortium, Norwalk, CT; Ravi Vij, Washington University School of Medicine, St. Louis, MO; Jean-Luc Harousseau, Institut de Canc\u00e9rlogie de l'Ouest Ren\u00e9 Gauducheau, Saint Herblain; Philippe Moreau, University Hospital, Nantes; Thierry Facon, Xavier Leleu, Service des Maladies du Sang Hopital Claude Huriez, Lille,..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L. Claire","family":"Tsao","sequence":"additional","affiliation":[{"name":"Sagar Lonial and Jonathan L. Kaufman, Winship Cancer Institute, Emory University, Atlanta, GA; Sagar Lonial, Ravi Vij, Jonathan L. Kaufman, and Sundar Jagannath, Multiple Myeloma Research Consortium, Norwalk, CT; Ravi Vij, Washington University School of Medicine, St. Louis, MO; Jean-Luc Harousseau, Institut de Canc\u00e9rlogie de l'Ouest Ren\u00e9 Gauducheau, Saint Herblain; Philippe Moreau, University Hospital, Nantes; Thierry Facon, Xavier Leleu, Service des Maladies du Sang Hopital Claude Huriez, Lille,..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Westland","sequence":"additional","affiliation":[{"name":"Sagar Lonial and Jonathan L. Kaufman, Winship Cancer Institute, Emory University, Atlanta, GA; Sagar Lonial, Ravi Vij, Jonathan L. Kaufman, and Sundar Jagannath, Multiple Myeloma Research Consortium, Norwalk, CT; Ravi Vij, Washington University School of Medicine, St. Louis, MO; Jean-Luc Harousseau, Institut de Canc\u00e9rlogie de l'Ouest Ren\u00e9 Gauducheau, Saint Herblain; Philippe Moreau, University Hospital, Nantes; Thierry Facon, Xavier Leleu, Service des Maladies du Sang Hopital Claude Huriez, Lille,..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anil K.","family":"Singhal","sequence":"additional","affiliation":[{"name":"Sagar Lonial and Jonathan L. Kaufman, Winship Cancer Institute, Emory University, Atlanta, GA; Sagar Lonial, Ravi Vij, Jonathan L. Kaufman, and Sundar Jagannath, Multiple Myeloma Research Consortium, Norwalk, CT; Ravi Vij, Washington University School of Medicine, St. Louis, MO; Jean-Luc Harousseau, Institut de Canc\u00e9rlogie de l'Ouest Ren\u00e9 Gauducheau, Saint Herblain; Philippe Moreau, University Hospital, Nantes; Thierry Facon, Xavier Leleu, Service des Maladies du Sang Hopital Claude Huriez, Lille,..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sundar","family":"Jagannath","sequence":"additional","affiliation":[{"name":"Sagar Lonial and Jonathan L. Kaufman, Winship Cancer Institute, Emory University, Atlanta, GA; Sagar Lonial, Ravi Vij, Jonathan L. Kaufman, and Sundar Jagannath, Multiple Myeloma Research Consortium, Norwalk, CT; Ravi Vij, Washington University School of Medicine, St. Louis, MO; Jean-Luc Harousseau, Institut de Canc\u00e9rlogie de l'Ouest Ren\u00e9 Gauducheau, Saint Herblain; Philippe Moreau, University Hospital, Nantes; Thierry Facon, Xavier Leleu, Service des Maladies du Sang Hopital Claude Huriez, Lille,..."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"233","reference":[{"key":"B1","volume-title":"SEER Cancer Statistics Review, 1975-2007","author":"Altekruse SF"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.4065\/79.7.867"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa043445"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa070596"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa070594"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-05-0577"},{"key":"B7","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1111\/j.1365-2141.2007.06841.x","volume":"140","author":"Reddy N","year":"2008","journal-title":"Br J Haematol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-08-107292"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-07-4246"},{"key":"B10","first-page":"112","author":"Garg TK","year":"2008","journal-title":"Blood"},{"key":"B11","first-page":"146","volume":"92","author":"Afar D","year":"2007","journal-title":"Haematologica"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-09-0483"},{"key":"B13","first-page":"110","author":"Rice AG","year":"2007","journal-title":"Blood"},{"key":"B14","first-page":"114","author":"Lonial S","year":"2009","journal-title":"Blood"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2404284"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2011.29.15_suppl.8076"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V98.1.210"},{"key":"B18","first-page":"116","author":"Richardson PG","year":"2010","journal-title":"Blood"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.26.4556"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.09.6305"}],"container-title":["Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/JCO.2011.37.2649","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,24]],"date-time":"2024-04-24T02:05:12Z","timestamp":1713924312000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/JCO.2011.37.2649"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,6,1]]},"references-count":20,"journal-issue":{"issue":"16","published-print":{"date-parts":[[2012,6,1]]}},"alternative-id":["10.1200\/JCO.2011.37.2649"],"URL":"https:\/\/doi.org\/10.1200\/jco.2011.37.2649","relation":{},"ISSN":["0732-183X","1527-7755"],"issn-type":[{"value":"0732-183X","type":"print"},{"value":"1527-7755","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,6,1]]}}}